Loading
Loading…
Loading…
| # | Schedule | Awarded To | Bids | Value |
|---|---|---|---|---|
| 1 | Schedule 3 | CROWN PHARMACEUTICALSLikely | 1 | ₹14,760 |
| 2 | Schedule 8 | Not yet disclosed by govt.Likely | 3 | - |
| 3 | Schedule 10 | CROWN PHARMACEUTICALSLikely | 1 | ₹51,840 |
| 4 | Schedule 13 | CROWN PHARMACEUTICALSLikely | 1 | ₹63,600 |
Tender Value
₹6.6 L
EMD Value
Exempted
Closing Date
7 Jun 2025, 8:00 pmClosed
Acyclovir Tablets (V2) (Q2)
Bicalutamide Tablets (V2) (Q2) Efavirenz Tablets (V2) (Q2)
Imatinib Tablet (Q2) Lamivudine + Nevirapine Tablets (V2) (Q2) (V2) (Q2)
Amiodarone Tablets (V2) (Q2) (V2) (Q2)
Budesonide + Formoterol Fumarate Respules (V2) (Q2) (V2) (Q2)
Itraconazole Capsule (Q2)
Ivermectin Tablet (Q2) (V2) (Q2)
Flunarizine Tablet (Q2)
7788728
GEM/2025/B/6184313
Two Packet Bid
Acyclovir Tablets (V2)
Jammu And Kashmir; Jammu
Item wise evaluation
PRODUCT
8 documents required · 8 mandatory
3 yrs
₹3
80%
| Item | Delivery Location | Qty | Delivery |
|---|---|---|---|
| Acyclovir Tablets (V2) (Q2) | - | - | - |
| Bicalutamide Tablets (V2) (Q2) Efavirenz Tablets (V2) (Q2) | - | - | - |
| Imatinib Tablet (Q2) Lamivudine + Nevirapine Tablets (V2) (Q2) (V2) (Q2) | - | - | - |
| Amiodarone Tablets (V2) (Q2) (V2) (Q2) | - | - | - |
| Budesonide + Formoterol Fumarate Respules (V2) (Q2) (V2) (Q2) | - | - | - |
| Itraconazole Capsule (Q2) | - | - | - |
| Ivermectin Tablet (Q2) (V2) (Q2) | - | - | - |
| Flunarizine Tablet (Q2) | - | - | - |
Exempted
8 Jun 2025
7 Jun 2025
7 Jun 2025
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
bid_7788728.pdf
GEM_BID
list-of-categories-where-trials-are-allowed_1712126171.pdf
OTHER
gtc.pdf
OTHER
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at .